Hollencrest Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.82K | Sell |
153
-152
| -50% | -$8.73K | ﹤0.01% | 833 |
|
|
2026
Q1 | $18.5K | Hold |
305
| – | – | ﹤0.01% | 735 |
|
|
2025
Q4 | $16.5K | Hold |
305
| – | – | ﹤0.01% | 741 |
|
|
2025
Q3 | $13.8K | Hold |
305
| – | – | ﹤0.01% | 754 |
|
|
2025
Q2 | $14.1K | Hold |
305
| – | – | ﹤0.01% | 715 |
|
|
2025
Q1 | $18.6K | Sell |
305
-187
| -38% | -$10.9K | ﹤0.01% | 689 |
|
|
2024
Q4 | $27.8K | Hold |
492
| – | – | ﹤0.01% | 622 |
|
|
2024
Q3 | $25.5K | Buy |
492
+187
| +61% | +$8.77K | ﹤0.01% | 632 |
|
|
2024
Q2 | $12.7K | Hold |
305
| – | – | ﹤0.01% | 724 |
|
|
2024
Q1 | $16.5K | Hold |
305
| – | – | ﹤0.01% | 657 |
|
|
2023
Q4 | $15.7K | Sell |
305
-24
| -7% | -$1.26K | ﹤0.01% | 670 |
|
|
2023
Q3 | $19.1K | Hold |
329
| – | – | ﹤0.01% | 637 |
|
|
2023
Q2 | $21K | Sell |
329
-750
| -70% | -$50.3K | ﹤0.01% | 652 |
|
|
2023
Q1 | $74.8K | Sell |
1,079
-35
| -3% | -$2.47K | 0.01% | 416 |
|
|
2022
Q4 | $80.2K | Sell |
1,114
-16,715
| -94% | -$1.26M | 0.01% | 366 |
|
|
2022
Q3 | $1.27M | Sell |
17,829
-770
| -4% | -$55.9K | 0.16% | 78 |
|
|
2022
Q2 | $1.43M | Buy |
18,599
+300
| +2% | +$22.8K | 0.17% | 78 |
|
|
2022
Q1 | $1.34M | Hold |
18,299
| – | – | 0.12% | 95 |
|
|
2021
Q4 | $1.14M | Buy |
18,299
+500
| +3% | +$29.3K | 0.09% | 112 |
|
|
2021
Q3 | $1.05M | Hold |
17,799
| – | – | 0.09% | 112 |
|
|
2021
Q2 | $1.19M | Hold |
17,799
| – | – | 0.11% | 102 |
|
|
2021
Q1 | $1.12M | Buy |
17,799
+4,100
| +30% | +$255K | 0.11% | 110 |
|
|
2020
Q4 | $850K | Buy |
13,699
+2,004
| +17% | +$123K | 0.09% | 125 |
|
|
2020
Q3 | $705K | Hold |
11,695
| – | – | 0.08% | 130 |
|
|
2020
Q2 | $688K | Buy |
+11,695
| New | +$700K | 0.09% | 121 |
|
|
2019
Q3 | – | Sell |
-14,009
| Closed | -$635K | – | 319 |
|
|
2019
Q2 | $635K | Sell |
14,009
-1,998
| -12% | -$93.1K | 0.08% | 144 |
|
|
2019
Q1 | $763K | Buy |
16,007
+6,403
| +67% | +$319K | 0.1% | 124 |
|
|
2018
Q4 | $499K | Sell |
9,604
-9,881
| -51% | -$531K | 0.07% | 157 |
|
|
2018
Q3 | $979K | Buy |
+19,485
| New | +$1.16M | 0.06% | 158 |
|
|
2018
Q2 | – | Sell |
-10,353
| Closed | -$655K | – | 324 |
|
|
2018
Q1 | $655K | Buy |
10,353
+1,300
| +14% | +$83.6K | 0.09% | 135 |
|
|
2017
Q4 | $555K | Buy |
9,053
+1,500
| +20% | +$93.8K | 0.07% | 157 |
|
|
2017
Q3 | $481K | Buy |
+7,553
| New | +$441K | 0.07% | 170 |
|
|
2017
Q1 | – | Sell |
-3,812
| Closed | -$222K | – | 367 |
|
|
2016
Q4 | $222K | Buy |
3,812
+5
| +0.1% | +$273 | 0.03% | 271 |
|
|
2016
Q3 | $206K | Sell |
3,807
-4,669
| -55% | -$300K | 0.03% | 314 |
|
|
2016
Q2 | $623K | Sell |
8,476
-987
| -10% | -$69.7K | 0.1% | 166 |
|
|
2016
Q1 | $604K | Buy |
9,463
+2,864
| +43% | +$181K | 0.1% | 157 |
|
|
2015
Q4 | $454K | Buy |
6,599
+1,826
| +38% | +$121K | 0.08% | 199 |
|
|
2015
Q3 | $283K | Sell |
4,773
-1,634
| -26% | -$104K | 0.05% | 255 |
|
|
2015
Q2 | $426K | Buy |
6,407
+1,257
| +24% | +$82.8K | 0.06% | 210 |
|
|
2015
Q1 | $332K | Buy |
5,150
+371
| +8% | +$23.2K | 0.04% | 257 |
|
|
2014
Q4 | $282K | Sell |
4,779
-634
| -12% | -$35.8K | 0.04% | 296 |
|
|
2014
Q3 | $277K | Buy |
5,413
+5
| +0.1% | +$250 | 0.04% | 298 |
|
|
2014
Q2 | $262K | Buy |
5,408
+537
| +11% | +$26.5K | 0.04% | 309 |
|
|
2014
Q1 | $253K | Buy |
4,871
+367
| +8% | +$19.5K | 0.04% | 305 |
|
|
2013
Q4 | $240K | Buy |
+4,504
| New | +$229K | 0.04% | 272 |
|
Other funds holding BMY
Hollencrest Capital Management's BMY Position: Q2 2026 in Review
Hollencrest Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 50% in Q2 2026, selling an estimated $8.73K and leaving 153 shares worth $8.82K. The position accounts for ﹤0.01% of the portfolio, ranked #833.
Hollencrest Capital Management first reported a position in BMY in Q4 2013 and has held it in 45 quarters since. The position peaked at $1.43M in Q2 2022. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Hollencrest Capital Management held 153 shares of Bristol-Myers Squibb worth $8.82K as of Q2 2026.
- Hollencrest Capital Management sold 152 Bristol-Myers Squibb shares in Q2 2026, an estimated $8.73K.
- Bristol-Myers Squibb made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #833 holding.
- Hollencrest Capital Management first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 45 quarters since.
- Hollencrest Capital Management's Bristol-Myers Squibb position peaked at $1.43M in Q2 2022.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.